Healthcare >> CEO Interviews >> December 5, 2001
ERAN BROSHY joined Ventiv Health, Inc., as Chief Executive Officer and
Director in June 1999, shortly before the company's spinoff from Snyder
Communications, and has led Ventiv Health for the entire time that it
has been a publically-traded company. Prior to joining Ventiv, Mr.
Broshy served as the partner responsible for the healthcare practice of
The Boston Consulting Group (BCG) across the Americas, and is a widely
recognized authority and frequent speaker on strategic issues in
pharmaceuticals and health care. During his 14-year tenure at BCG, Mr.
Broshy consulted widely with senior executives from a number of the
major global pharmaceutical manufacturers, managed care organizations
and academic medical centers, and advised on a range of strategic,
organizational and operational issues. Mr. Broshy has also served as
President and Chief Executive Officer of Coelacanth Corporation, a
privately-held biotechnology company. He currently also serves as a
Director of Neurogen Corporation. Mr. Broshy is a graduate of Harvard
University (MBA), Stanford University (MS) and Massachusetts Institute
of Technology (BS). Profile
Ventiv Health, Inc.?
Mr. Broshy: Ventiv has been a public company for a little over two
years, since September 1999. We
